Systeme und Verfahren zur Erzeugung von Umnutzung von Wirkstoffkandidaten für Zielerkrankungen
Anmelder: Tata Consultancy Services Limited 🇮🇳
Details
- Veröffentlichungs-Nr.
- EP4723129
- Anmeldetag
- 12. September 2025
- Veröffentlichung
- 8. April 2026
- Rechtsraum
- EP
Abstract
Development of a new drug molecule on average requires an expenditure of US$2-3 billion and a duration of at least 13-15 years. Subsequently, repurposing the existing drugs outside the scope of the original medical indications, has attracted serious consideration. Present disclosure provides a system and method for recommending drug candidates for a target disease by generating drug-refined Medical Subject Headings (MeSH) terms frequency matrix using MeSH terms assigned to Pubmed articles. Further, topic modelling is performed on the drug-refined MeSH terms frequency matrix to generate drug-topic conditional probabilities, and drug-drug distance is computed using Kullback-Leibler divergence. The drugs are then clustered and unknown drugs of a target disease are shortlisted from a cluster with known drugs based on predicted targets and indications of unknown and known drugs. A subset of shortlisted unknown drugs is recommended as a new candidate for target disease based on supporting literature evidence.
Anmelder
- Firma
- Tata Consultancy Services Limited
- Land
- 🇮🇳 Indien
Indisches IT-Dienstleistungs- und Beratungsunternehmen, Teil der Tata Group. Bietet Softwareentwicklung, IT-Consulting, Outsourcing und digitale Transformationslösungen für Unternehmenskunden weltweit an.
1.851 Patente in unserer Datenbank
Boehmert & Boehmert geht auf die Zulassung von Dr. Karl Boehmert 1931 in Berlin zurück. Mit Standorten in Deutschland, Alicante, Paris und Shanghai bietet die Kanzlei IP aus einer Hand und legt besonderen Wert auf persönliche Mandantenbetreuung statt Anonymität.